CD19 and acute myeloid leukemia: Current phase I/II clinical trials that engineer NK-92 cell lines with CARs to target CD19 (NCT02892695), CD33 (NCT02944162), CD7 (NCT02742727) on acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) cells are ongoing.